{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:09:44Z","timestamp":1785283784812,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01445-3","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T08:27:44Z","timestamp":1755592064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological Strategies for the Treatment of Restless Legs Syndrome"],"prefix":"10.1007","volume":"25","author":[{"given":"David","family":"Anguizola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Garcia Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Lopez Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Garcia-Borreguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"1445_CR1","doi-asserted-by":"publisher","first-page":"e13783","DOI":"10.1111\/jsr.13783","volume":"32","author":"A Brostrom","year":"2023","unstructured":"Brostrom A, Alimoradi Z, Lind J, Ulander M, Lundin F, Pakpour A. Worldwide Estimation of restless legs syndrome: a systematic review and meta-analysis of prevalence in the general adult population. J Sleep Res. 2023;32:e13783.","journal-title":"J Sleep Res"},{"key":"1445_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.autneu.2019.02.006","volume":"218","author":"A Silvani","year":"2019","unstructured":"Silvani A. Sleep disorders, nocturnal blood pressure, and cardiovascular risk: A translational perspective. Auton Neuroscience: Basic Clin. 2019;218:31\u201342.","journal-title":"Auton Neuroscience: Basic Clin"},{"key":"1445_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jsmc.2021.02.005","volume":"16","author":"B Wipper","year":"2021","unstructured":"Wipper B, Winkelman JW. The Long-Term psychiatric and cardiovascular morbidity and mortality of restless legs syndrome and periodic limb movements of sleep. Sleep Med Clin. 2021;16:279\u201388.","journal-title":"Sleep Med Clin"},{"key":"1445_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s13311-021-01019-4","volume":"18","author":"TR Gossard","year":"2021","unstructured":"Gossard TR, Trotti LM, Videnovic A, St Louis EK. Restless legs syndrome: contemporary diagnosis and treatment. Neurotherapeutics. 2021;18:140\u201355.","journal-title":"Neurotherapeutics"},{"key":"1445_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41606-020-00057-9","volume":"5","author":"R Oroz","year":"2021","unstructured":"Oroz R, Kung S, Croarkin PE, Cheung J. Transcranial magnetic stimulation therapeutic applications on sleep and insomnia: a review. Sleep Sci Pract. 2021;5:3.","journal-title":"Sleep Sci Pract"},{"key":"1445_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.sleep.2024.08.017","volume":"122","author":"H Singh","year":"2024","unstructured":"Singh H, Baker FC, Ojile J, Adlou B, Kolotovska V, Rigot SK, et al. Efficacy and safety of TOMAC for treatment of medication-naive and medication-refractory restless legs syndrome: A randomized clinical trial and meta-analysis. Sleep Med. 2024;122:141\u20138.","journal-title":"Sleep Med"},{"key":"1445_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.smrv.2018.01.001","volume":"41","author":"D Garcia-Borreguero","year":"2018","unstructured":"Garcia-Borreguero D, Cano-Pumarega I, Marulanda R. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease). Sleep Med Rev. 2018;41:50\u201360.","journal-title":"Sleep Med Rev"},{"key":"1445_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.27260","volume":"33","author":"J Winkelmann","year":"2018","unstructured":"Winkelmann J, Allen RP, Hogl B, Inoue Y, Oertel W, Salminen AV, et al. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017). Mov Disord. 2018;33:1077\u201391.","journal-title":"Mov Disord"},{"key":"1445_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nrneurol.2015.122","volume":"11","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Restless legs syndrome-current therapies and management of augmentation. Nat Rev Neurol. 2015;11:434\u201345.","journal-title":"Nat Rev Neurol"},{"key":"1445_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jsmc.2021.02.003","volume":"16","author":"LMB P","year":"2021","unstructured":"P LMB, Castro-Villacanas ESSA, Garcia-Borreguero A. Restless legs syndrome: challenges to treatment. Sleep Med Clin. 2021;16:269\u201377.","journal-title":"Sleep Med Clin"},{"key":"1445_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","volume":"21","author":"D Garcia-Borreguero","year":"2016","unstructured":"Garcia-Borreguero D, Silber MH, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1\u201311.","journal-title":"Sleep Med"},{"key":"1445_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.sleep.2021.07.027","volume":"85","author":"C Garcia-Malo","year":"2021","unstructured":"Garcia-Malo C, Novo-Ponte S, Castro-Villacanas Farzamnia A, Boi S, Miranda Castillo C, Romero Peralta S, et al. Correlation between systemic iron parameters and substantia Nigra iron stores in restless legs syndrome. Sleep Med. 2021;85:191\u20135.","journal-title":"Sleep Med"},{"key":"1445_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41572-021-00311-z","volume":"7","author":"M Manconi","year":"2021","unstructured":"Manconi M, Garcia-Borreguero D, Schormair B, Videnovic A, Berger K, Ferri R, et al. Restless legs syndrome. Nat Rev Dis Primers. 2021;7:80.","journal-title":"Nat Rev Dis Primers"},{"key":"1445_CR14","doi-asserted-by":"crossref","unstructured":"Earley CJ, Garcia-Borreguero D, Falone M, Winkelman JW. Clinical efficacy and safety of intravenous ferric carboxymaltose for treatment of restless legs syndrome: a multicenter, randomized, placebo-controlled clinical trial. Sleep. 2024;47.zsae095.","DOI":"10.1093\/sleep\/zsae095"},{"key":"1445_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.sleep.2023.10.022","volume":"112","author":"YS Li","year":"2023","unstructured":"Li YS, Yeh WC, Hsu CY. Association of low serum ferritin levels with augmentation in patients with restless legs syndrome: A systematic review and meta-analysis. Sleep Med. 2023;112:173\u201380.","journal-title":"Sleep Med"},{"key":"1445_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5664\/jcsm.11390","volume":"21","author":"JW Winkelman","year":"2025","unstructured":"Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2025;21:137\u201352.","journal-title":"J Clin Sleep Med"},{"key":"1445_CR17","doi-asserted-by":"publisher","first-page":"109329","DOI":"10.1016\/j.neuropharm.2022.109329","volume":"223","author":"S Ferre","year":"2023","unstructured":"Ferre S, Sarasola LI, Quiroz C, Ciruela F. Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum. Neuropharmacology. 2023;223:109329.","journal-title":"Neuropharmacology"},{"key":"1445_CR18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.sleep.2015.05.028","volume":"16","author":"T Mitterling","year":"2015","unstructured":"Mitterling T, Heidbreder A, Stefani A, Fritz J, Ulmer H, Poewe W, et al. Natural course of restless legs syndrome\/Willis-Ekbom disease: long-term observation of a large clinical cohort. Sleep Med. 2015;16:1252\u20138.","journal-title":"Sleep Med"},{"key":"1445_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","volume":"12","author":"N Silver","year":"2011","unstructured":"Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440\u20134.","journal-title":"Sleep Med"},{"key":"1445_CR20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","volume":"13","author":"MC Lipford","year":"2012","unstructured":"Lipford MC, Silber MH. Long-term use of Pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13:1280\u20135.","journal-title":"Sleep Med"},{"key":"1445_CR21","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4067\/S0034-98872016001200007","volume":"144","author":"CM Miranda","year":"2016","unstructured":"Miranda CM, Hudson AL. [Restless legs syndrome: long-term follow-up of a series of patients]. Rev Med Chil. 2016;144:1561\u20136.","journal-title":"Rev Med Chil"},{"key":"1445_CR22","doi-asserted-by":"crossref","unstructured":"Winkelman JW. High National rates of high-dose dopamine agonist prescribing for restless legs syndrome. Sleep. 2022;45.zsab212.","DOI":"10.1093\/sleep\/zsab212"},{"key":"1445_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11325-021-02353-9","volume":"26","author":"T Wang","year":"2022","unstructured":"Wang T, Ying M, Zhao R, Zhu D, Zhang L. Augmentation in patients with restless legs syndrome receiving Pramipexole therapy: a retrospective study in a single center from China. Sleep Breath. 2022;26:373\u201380.","journal-title":"Sleep Breath"},{"key":"1445_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1303646","volume":"370","author":"RP Allen","year":"2014","unstructured":"Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of Pregabalin with Pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621\u201331.","journal-title":"N Engl J Med"},{"key":"1445_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2377-10-86","volume":"10","author":"B Hogl","year":"2010","unstructured":"Hogl B, Oertel WH, Stiasny-Kolster K, Geisler P, Benes H, Garcia-Borreguero D, et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol. 2010;10:86.","journal-title":"BMC Neurol"},{"key":"1445_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Hogl B, et al. The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the international restless legs syndrome study group. Sleep Med. 2013;14:675\u201384.","journal-title":"Sleep Med"},{"key":"1445_CR27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1212\/WNL.56.10.1399","volume":"56","author":"K Stiasny","year":"2001","unstructured":"Stiasny K, Wetter TC, Winkelmann J, Brandenburg U, Penzel T, Rubin M, et al. Long-term effects of Pergolide in the treatment of restless legs syndrome. Neurology. 2001;56:1399\u2013402.","journal-title":"Neurology"},{"key":"1445_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14656566.2013.758251","volume":"14","author":"E Dohin","year":"2013","unstructured":"Dohin E, Hogl B, Ferini-Strambi L, Schollmayer E, Fichtner A, Bauer L, et al. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1\u20133\u00a0mg\/24\u00a0h for up to 5 years. Expert Opin Pharmacother. 2013;14:15\u201325.","journal-title":"Expert Opin Pharmacother"},{"key":"1445_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1586\/14737175.2016.1158103","volume":"16","author":"A Ramirez-Zamora","year":"2016","unstructured":"Ramirez-Zamora A, Gee L, Boyd J, Biller J. Treatment of impulse control disorders in parkinson\u2019s disease: practical considerations and future directions. Expert Rev Neurother. 2016;16:389\u201399.","journal-title":"Expert Rev Neurother"},{"key":"1445_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.psychres.2014.12.005","volume":"225","author":"P Tanwani","year":"2015","unstructured":"Tanwani P, Fernie BA, Nikcevic AV, Spada MM. A systematic review of treatments for impulse control disorders and related behaviours in parkinson\u2019s disease. Psychiatry Res. 2015;225:402\u20136.","journal-title":"Psychiatry Res"},{"key":"1445_CR31","first-page":"81","volume":"33","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33:81\u20137.","journal-title":"Sleep"},{"key":"1445_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/WNF.0b013e3182087d48","volume":"34","author":"AL Ellenbogen","year":"2011","unstructured":"Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, et al. A 52-week study of Gabapentin Enacarbil in restless legs syndrome. Clin Neuropharmacol. 2011;34:8\u201316.","journal-title":"Clin Neuropharmacol"},{"key":"1445_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1474-4422(13)70239-4","volume":"12","author":"C Trenkwalder","year":"2013","unstructured":"Trenkwalder C, Benes H, Grote L, Garcia-Borreguero D, Hogl B, Hopp M, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141\u201350.","journal-title":"Lancet Neurol"},{"key":"1445_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40265-021-01494-1","volume":"81","author":"U Bonnet","year":"2021","unstructured":"Bonnet U, McAnally H, Scherbaum N. Comment on abuse and misuse of Pregabalin and gabapentin: A systematic review update. Drugs. 2021;81:611\u20134.","journal-title":"Drugs"},{"key":"1445_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1001\/jamainternmed.2013.3733","volume":"173","author":"TJ Wilt","year":"2013","unstructured":"Wilt TJ, MacDonald R, Ouellette J, Khawaja IS, Rutks I, Butler M, et al. Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis. JAMA Intern Med. 2013;173:496\u2013505.","journal-title":"JAMA Intern Med"},{"key":"1445_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00023210-200418010-00003","volume":"18","author":"S Happe","year":"2004","unstructured":"Happe S, Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs. 2004;18:27\u201336.","journal-title":"CNS Drugs"},{"key":"1445_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12987-020-00190-8","volume":"17","author":"JR Connor","year":"2020","unstructured":"Connor JR, Duck K, Patton S, Simpson IA, Trotti LM, Allen R, et al. Evidence for communication of peripheral iron status to cerebrospinal fluid: clinical implications for therapeutic strategy. Fluids Barriers CNS. 2020;17:28.","journal-title":"Fluids Barriers CNS"},{"key":"1445_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.lab.2005.06.011","volume":"147","author":"SL Clardy","year":"2006","unstructured":"Clardy SL, Earley CJ, Allen RP, Beard JL, Connor JR. Ferritin subunits in CSF are decreased in restless legs syndrome. J Lab Clin Med. 2006;147:67\u201373.","journal-title":"J Lab Clin Med"},{"key":"1445_CR39","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.54.8.1698","volume":"54","author":"CJ Earley","year":"2000","unstructured":"Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54:1698\u2013700.","journal-title":"Neurology"},{"key":"1445_CR40","doi-asserted-by":"crossref","unstructured":"Garcia-Borreguero D, Allen RP, Kohnen R, H\u00f6gl B, Trenkwalder C, Oertel W et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8:520\u2013\u200930.","DOI":"10.1016\/j.sleep.2007.03.022"},{"key":"1445_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/mds.24889","volume":"27","author":"D Garcia-Borreguero","year":"2012","unstructured":"Garcia-Borreguero D, Hogl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27:277\u201383.","journal-title":"Mov Disord"},{"issue":"Suppl","key":"1445_CR42","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S1389-9457(02)00144-2","volume":"3","author":"L Ferini-Strambi","year":"2002","unstructured":"Ferini-Strambi L. Restless legs syndrome augmentation and Pramipexole treatment. Sleep Med. 2002;3(Suppl):S23\u20135.","journal-title":"Sleep Med"},{"key":"1445_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.sleep.2007.03.023","volume":"8","author":"D Garcia-Borreguero","year":"2007","unstructured":"Garcia-Borreguero D, Kohnen R, Hogl B, Ferini-Strambi L, Hadjigeorgiou GM, Hornyak M, et al. Validation of the augmentation severity rating scale (ASRS): a multicentric, prospective study with Levodopa on restless legs syndrome. Sleep Med. 2007;8:455\u201363.","journal-title":"Sleep Med"},{"key":"1445_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.sleep.2010.12.007","volume":"12","author":"B H\u00f6gl","year":"2011","unstructured":"H\u00f6gl B, Garcia-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W, et al. Efficacy and augmentation during 6 months of double-blind Pramipexole for restless legs syndrome. Sleep Med. 2011;12:351\u201360.","journal-title":"Sleep Med"},{"key":"1445_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.sleep.2011.03.003","volume":"12","author":"RP Allen","year":"2011","unstructured":"Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and Levodopa usage in a community sample. Sleep Med. 2011;12:431\u20139.","journal-title":"Sleep Med"},{"key":"1445_CR46","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/archneur.61.9.1393","volume":"61","author":"W Ondo","year":"2004","unstructured":"Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004;61:1393\u20137.","journal-title":"Arch Neurol"},{"key":"1445_CR47","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/sleep\/26.7.819","volume":"26","author":"MH Silber","year":"2003","unstructured":"Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep. 2003;26:819\u201321.","journal-title":"Sleep"},{"key":"1445_CR48","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/sleep\/20.10.878","volume":"20","author":"MH Silber","year":"1997","unstructured":"Silber MH, Shepard JW Jr., Wisbey JA. Pergolide in the management of restless legs syndrome: an extended study. Sleep. 1997;20:878\u201382.","journal-title":"Sleep"},{"key":"1445_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","volume":"5","author":"JW Winkelman","year":"2004","unstructured":"Winkelman JW, Johnston L. Augmentation and tolerance with long-term Pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9\u201314.","journal-title":"Sleep Med"},{"key":"1445_CR50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1212\/WNL.46.1.92","volume":"46","author":"AS Walters","year":"1996","unstructured":"Walters AS, Hickey K, Maltzman J, Verrico T, Joseph D, Hening W, et al. A questionnaire study of 138 patients with restless legs syndrome: the \u2018Night-Walkers\u2019 survey. Neurology. 1996;46:92\u20135.","journal-title":"Neurology"},{"key":"1445_CR51","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1212\/WNL.43.2.445","volume":"43","author":"C Guilleminault","year":"1993","unstructured":"Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology. 1993;43:445.","journal-title":"Neurology"},{"key":"1445_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.sleep.2019.09.020","volume":"66","author":"C Garcia-Malo","year":"2020","unstructured":"Garcia-Malo C, Wanner V, Miranda C, Romero Peralta S, Agudelo L, Cano-Pumarega I, et al. Quantitative transcranial sonography of the substantia Nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome. Sleep Med. 2020;66:123\u20139.","journal-title":"Sleep Med"},{"key":"1445_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.sleep.2017.11.1126","volume":"41","author":"RP Allen","year":"2018","unstructured":"Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome\/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27\u201344.","journal-title":"Sleep Med"},{"key":"1445_CR54","unstructured":"Garcia Malo C, G-BD, Silber M. Efficacy and safety of intravenous iron in patients with normal serum ferritin levels: A stratified sub-analysis. JClinSleepMed."},{"key":"1445_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/mds.21230","volume":"22","author":"J Godau","year":"2007","unstructured":"Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Substantia Nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord. 2007;22:187\u201392.","journal-title":"Mov Disord"},{"key":"1445_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.22391","volume":"24","author":"J Godau","year":"2009","unstructured":"Godau J, Manz A, Wevers AK, Gaenslen A, Berg D. Sonographic substantia Nigra hypoechogenicity in polyneuropathy and restless legs syndrome. Mov Disord. 2009;24:133\u20137.","journal-title":"Mov Disord"},{"key":"1445_CR57","doi-asserted-by":"crossref","unstructured":"Iftikhar IH, Alghothani L, Trotti LM. Gabapentin enacarbil, Pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol. 2017;24(12):1446\u20131456.ene.13449.","DOI":"10.1111\/ene.13449"},{"key":"1445_CR58","doi-asserted-by":"publisher","first-page":"635","DOI":"10.5665\/sleep.3558","volume":"37","author":"D Garcia-Borreguero","year":"2014","unstructured":"Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37:635\u201343.","journal-title":"Sleep"},{"key":"1445_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.sleep.2018.11.025","volume":"55","author":"D Garcia-Borreguero","year":"2019","unstructured":"Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V. Reduced response to Gabapentin Enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. 2019;55:74\u201380.","journal-title":"Sleep Med"},{"key":"1445_CR60","doi-asserted-by":"crossref","unstructured":"Garcia-Borreguero D, Anguizola D, Carvallo C, Lopez A, Garcia Aragon A, Moncada B et al. Subclinical augmentation in relation to previous dopaminergic treatment in patients with restless legs syndrome: A post hoc analysis of two randomized, Placebo-Controlled, Crossover Trials. CNS Drugs. 2025;39:779\u2013793.","DOI":"10.1007\/s40263-025-01192-6"},{"key":"1445_CR61","doi-asserted-by":"publisher","first-page":"j104","DOI":"10.1136\/bmj.j104","volume":"356","author":"D Garcia-Borreguero","year":"2017","unstructured":"Garcia-Borreguero D, Cano-Pumarega I. New concepts in the management of restless legs syndrome. BMJ. 2017;356:j104.","journal-title":"BMJ"},{"key":"1445_CR62","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1474-4422(18)30311-9","volume":"17","author":"C Trenkwalder","year":"2018","unstructured":"Trenkwalder C, Allen R, Hogl B, Clemens S, Patton S, Schormair B, et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 2018;17:994\u20131005.","journal-title":"Lancet Neurol"},{"key":"1445_CR63","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40263-015-0250-2","volume":"29","author":"S Mackie","year":"2015","unstructured":"Mackie S, Winkelman JW. Long-Term treatment of restless legs syndrome (RLS): an approach to management of worsening symptoms, loss of efficacy, and augmentation. CNS Drugs. 2015;29:351\u20137.","journal-title":"CNS Drugs"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01445-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01445-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01445-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:10:14Z","timestamp":1757401814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01445-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01445-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"1 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diego Garcia-Borreguero has performed consulting work for Emalex Biosciences, Synendos Therapeutics, and PsychoGenics Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"60"}}